Alder Biopharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bothell WA United States (2004)
Status: Acquired by Lundbeck (2019)

Organization Overview

First Clinical Trial
2008
NCT00866970
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Alder BioPharmaceuticals | Alder Biopharmaceuticals, Inc. | Cady, Roger, M.D.

Active Ingredients

Drugs in Phase 4 Trials (2)

frovatriptan (frova) (1 trial)

topiramate (topamax) (1 trial)

Drugs in Phase 3 Trials (1)

eptinezumab (Vyepti) (7 trials)

Drugs in Phase 2 Trials (4)

adalimumab (humira) (1 trial)

clazakizumab (8 trials)

naltrexone (revia) (1 trial)

vvd-101 (1 trial)

Drugs in Phase 1 Trials (1)

sumatriptan (zecuity) (2 trials)

Drugs in Other Trials (1)

ald1910 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Psoriatic (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Cachexia (Phase 2)

Crohn Disease (Phase 2)

Fatigue (Phase 2)

Headache (Phase 2)

Head and Neck Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Migraine Disorders (Phase 4)

Mucositis (Phase 2)

Stomatitis (Phase 2)

Wasting Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 9